Cidara Aims For Treatment, Prophylaxis Claims For Novel Antifungal

Cidara Therapeutics, Inc. is running Phase III trials for two separate indications of its novel echinocandin antifungal agent, but while rezafungin might reach market first as a treatment for candidemia and invasive candidiasis, the firm says a second indication for infection prophylaxis in hematologic cancer settings may offer improved outcomes for patients and cost savings for the health care system.

The San Diego-based company held a research and development day on 21 September, detailing its two pivotal studies for rezafungin along with its commercial expectations for the drug. Cidara hopes to bring rezafungin to market in 2023 as a novel, first-line treatment for candidemia and invasive candidiasis, with a label expansion in 2024 for prophylaxis of fungal infections in patients receiving bone marrow transplants for cancers such as acute myeloid leukemia, acute lymphoblastic leukemia and chronic lymphocytic leukemia